Product category:
Cell/tissue handling and counting
News Release from: Bionas | Subject: Bionas 2500
Edited by the Laboratorytalk Editorial
Team on 09 November 2006
Cell profiling device chosen for target
validation
Bionas and Solvay Pharmaceuticals Research Laboratories report that the Bionas 2500 analysing system has been recognised to be a valuable tool for target validation studies
"It is known that angiotensin 1-8 (angiotensin II) acts via two receptors "The AT1 receptor mediates vasoconstriction upon stimulation, whereas the AT2 receptor is implicated in hypotensive effects
This article was originally published on Laboratorytalk on 22 Aug 2006 at 8.00am (UK)
Related stories
In vitro profiling of cell metabolic activity
Bionas has launched a device for in vitro profiling the metabolic activity of cells to understand cellular function
"However, the mechanism through which angiotensin 1-7 induces its powerful hypotensive effect were unclear," explains Eric Ronken, principal scientist at Solvay.
On-line monitoring of endothelial cell physiology and its changes upon challenges by angiotensin 1-7 helped in delineating the mechanism of action by this peptide.
The Bionas 2500 analysing system is well suited for such experiments, as it measures cellular acidification, oxygen consumption and cell adhesion simultaneously in a label-free and non-invasive way.
"The Bionas system allows us to extend and optimise target validation studies by bringing the targets back into their physiological context", says Ronken.
The Bionas 2500 analysing system gives a complete overview over the physiologic state of cells.
It can be used to discriminate between different signal transduction pathways allowing target validation studies at an early stage in the drug discovery process.
Recently, Bionas announced the usefulness of its device to predict liver toxicity in primary human hepatocytes and standardised HepG2 cells.
• Bionas: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page

